spacer
home > pmps > winter 2019 > the heart of healthcare
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Heart of Healthcare

Over the last decade, many pharmaceutical companies have moved from mass market drug development to investing in niche speciality medicines. This shift in the pharma industry has been driven by the recognition that the sector’s traditional blockbuster model had become unsustainable.

This is good news for patients with rare diseases. The rise of speciality treatments for chronic, complex, and rare conditions has seen many breakthrough treatments being brought to market and offering new hope to patients.

According to IQVIA (formerly Quintiles and IMS Health), speciality medicines have enjoyed a decade of continued growth, which has put them on course to overtake the value of spending on traditional drugs in many of the world’s biggest pharma markets by 2022.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Jonathan Chapper is the CEO at CHAPPER healthcare. He joined CHAPPER healthcare in 2013 from a successful career in law, where he worked at leading city law firms, as well as in an investment bank. Jonathan brought with him a wealth of commercial and legal experience, which he now applies to the pharma industry. CHAPPER healthcare is a leading specialist wholesaler and distributor and supplies pharmaceuticals to over 60 countries worldwide.
spacer
Jonathan Chapper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Francine Lane Recipient of 2019 DIA Global Inspire Award

JERSEY CITY – March 21, 2019 – Francine Lane, TrialScope Vice President of Global Transparency, has received a 2019 Global Inspire Award from the Drug Information Association (DIA). Lane, chair of the DIA’s Clinical Trial Disclosure Community, and Robert Paarlberg, past chair, are co-recipients of the Community Engagement Award. The award recognizes DIA community chairs for consistently driving engagement while advancing knowledge and thought leadership within their membership communities.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

PPMA Total Show

1-3 October 2019, Birmingham

About PPMA Total Show PPMA Total is one of UK’s largest processing and packaging machinery exhibitions. Building on the success of the PPMA Show in 2018, PPMA Total returns to the NEC, Birmingham, on 1-3 October 2019 for another show-stopping event.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement